Secretive data-analytics company Palantir is developing a system to help local authorities decide where to allocate COVID-19 vaccines, the Wall Street Journal reported.
The system is called Tiberius, and is named after Captain Kirk from the “Star Trek” franchise.
A document seen by the Journal said Tiberius will analyze “demographic, employment, and public health data” to aid local officials in deciding high-priority populations to vaccinate.
Palantir, cofounded by Silicon Valley mogul and vocal Trump-supporter Peter Thiel, has come under fire from human rights groups in the past for its contracts with the US government.
Visit Business Insider’s homepage for more stories.
Data-analytics firm Palantir, which has drawn fire from human rights groups for its US government contracts, is reportedly working on a tool to help local authorities decide where to distribute COVID-19 vaccines.
The Wall Street Journal reported the news on Thursday, citing state and local health officials briefed on
Big data company Palantir is working with US health officials on a project to track the production and distribution of future Covid-19 vaccines.
The project first reported by the Wall Street Journal and confirmed by AFP, would use data science to help manage the deployment of any vaccines.
Palantir, which has drawn fire for its police and homeland security projects and for one of its founders’ close ties to President Donald Trump, did not comment on the report.
The Journal reported that the software system with the code name Tiberius could help identify high-priority populations at highest risk of infection but that the deal could draw fire by allowing the private company access to sensitive health information.
At least one pharmaceutical firm has indicated it will seek authorization for a vaccine in the US in November.
Palantir, which last month listed shares on the New York Stock Exchange, has defended
Ten months in, there are more than 8 million confirmed cases of Covid-19 in the U.S. and over 40 million cases worldwide, adding new urgency to the search for a vaccine. But as the pandemic continues to rage unabated, structural weaknesses in how we research, develop, and distribute medicines have come into sharp relief, raising questions about who will be able to access an eventual vaccine. Priti Krishtel, co-founder of I-MAK, sat down with Ashoka to discuss myths and reality in America’s quest for immunity.
Ashoka: What can we expect when a vaccine finally goes to market?
Priti Krishtel: The reality is that a vaccine is no silver bullet. Some people are going to get it first and some people aren’t going to get it at all. We’ve seen that play out with personal protective equipment, with ventilators, with testing. Professional basketball players
(Reuters) – The National Health Service (NHS) is in talks with the British Medical Association (BMA) and others around mobilising the rollout of a potential COVID-19 vaccine from December, Pulse website for health professionals reported on Thursday.
There is optimism around the first cohorts being given a vaccine in December but there is a 50/50 chance of the vaccine being available by that time, Pulse https://bit.ly/3lQhtJt reported, citing a person close to the discussions.
Talks are taking place between NHS England, the BMA and other groups over who will administer vaccines and who will receive it first, Pulse reported, citing multiple sources.
The government had proposed in August to allow more healthcare workers to administer vaccines.
There is debate on whether the first people to be vaccinated will be care home patients and their staff, or health care professionals, including general practitioners.